The prominence of the dosage form design to treat ocular diseases (2020)
Campos, Patrícia Mazureki; Petrilli, Raquel; Lopez, Renata Fonseca Vianna 
Source: International Journal of Pharmaceutics. Unidade: FCFRP
Subjects: BIODISPONIBILIDADE, NANOTECNOLOGIA, OLHO, IONTOFORESE, GEL (FORMAS FARMACÊUTICAS), FORMAS FARMACÊUTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Patrícia Mazureki e PETRILLI, Raquel e LOPEZ, Renata Fonseca Vianna. The prominence of the dosage form design to treat ocular diseases. International Journal of Pharmaceutics, v. 586, p. 1-13, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ijpharm.2020.119577. Acesso em: 18 fev. 2026.APA
Campos, P. M., Petrilli, R., & Lopez, R. F. V. (2020). The prominence of the dosage form design to treat ocular diseases. International Journal of Pharmaceutics, 586, 1-13. doi:10.1016/j.ijpharm.2020.119577NLM
Campos PM, Petrilli R, Lopez RFV. The prominence of the dosage form design to treat ocular diseases [Internet]. International Journal of Pharmaceutics. 2020 ; 586 1-13.[citado 2026 fev. 18 ] Available from: https://doi.org/10.1016/j.ijpharm.2020.119577Vancouver
Campos PM, Petrilli R, Lopez RFV. The prominence of the dosage form design to treat ocular diseases [Internet]. International Journal of Pharmaceutics. 2020 ; 586 1-13.[citado 2026 fev. 18 ] Available from: https://doi.org/10.1016/j.ijpharm.2020.119577
